Biotech Stocks Reviews
- Highlights of ASCO 2023 Abstracts
Fri, May 26
A few insights/notes from the ASCO abstracts that were released Thursday afternoon. ADCs Stay Winning · more » - Oral Obesity Treatments Making Waves
Tue, May 23
Biotech is bouncing back from the FTC news that raised concerns over MA activity (read detailshere). · more » - FTC Pauses Biotech Rally, But Show Must Go On
Tue, May 16
The biotech rally has been put on pause on news of the FTC lawsuit to block Amgen’s (AMGN) acquisition · more » - Obesity Proving to Be a Big Pharma Game
Thu, May 11
Eli Lilly and Novo Nordisk have established a stronghold in the $50B+ obesity opportunity. Validated · more » - Biotech Basics: Tactics Used To Spin Data
Tue, May 9
In the last Biotech Basics notes, we covered how to interpret data readouts, and what determines a · more » - Lilly’s Donanemab Data a Big Leap for Alzheimer’s
Thu, May 4
Eli Lilly (LLY) lifted the bio market yesterday after their amyloid targeting therapy, donanemab, showed · more » - Big Pharma in Shopping Mode for 2023
Wed, May 3
2023 has already brought several high-profile MA deals, as pharma giants are sitting on an estimated · more » - Biotech Basics: Interpreting Data Readouts
Fri, Apr 28
In the last Biotech Basics notes, we covered how to spot incoming financings (read here) and how · more » - Sentiment Check – Bio M&A Is Picking Up
Fri, Apr 21
Last week we wrote how the growth in venture capital funds for Q1 2023 was an early sign that private · more »